IDEAYA Biosciences shares jumped after the company posted additional positive interim results from its Phase 2 clinical trial evaluating its darovasertib.
IDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line Metas streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Confirmed overall response rate of 45%, disease control rate of 90% and median PFS of ~7 months in 20 evaluable First-Line MUM patientsBased on FDA meeting, initiating Phase 2/3 registrational. | April 23, 2023
Once again, the US Preventive Services Task Force has concluded that there is insufficient evidence on the balance of benefits vs the harms of screening asymptomatic patients for skin cancer.